Acesso aberto Acesso aberto  Acesso é fechado Acesso está concedido  Acesso é fechado Acesso é pago ou somente para assinantes

Volume 27, Nº 10 (2020)

Articles

NEWS OF MEDICINE

- -.
Pharmateca. 2020;27(10):6-7
pages 6-7 views

Management of patients with community-acquired pneumonia in outpatient settings

Sinopalnikov A.

Resumo

Pneumonia remains a serious public health problem due to unacceptably high morbidity and mortality. Among the issues that need to be addressed, one should first of all include difficulties in establishing the initial clinical diagnosis of pneumonia, stratification of the risk of an unfavorable outcome of the disease, optimization of the choice of empirical antibiotic therapy, the relative shortage of new antibiotics, and the importance of knowing the local characteristics of the microbiological sensitivity of pneumotropic microorganisms. The article discusses the problem of managing adult patients with community-acquired pneumonia (CAP). Information on the epidemiology, diagnosis, stratification of CAP patients according to the risk of an unfavorable outcome of the disease is presented in order to determine patients of this category who could receive outpatient treatment without compromising the ultimate efficacy and safety, as well as antibacterial therapy of CAP patients in outpatient settings, including with the use of new antibiotics.
Pharmateca. 2020;27(10):8-18
pages 8-18 views

Algorithm of respiratory support for COVID-19 patients

Babak S., Gorbunova M., Malyavin A.

Resumo

The coronavirus disease (COVID-19) pandemic, caused by the highly contagious SARS-CoV-2 coronavirus, is still at its peak, causing thousands of deaths every week. The current survival rate of COVID-19 patients with severe course of disease depends entirely on the provision of effective therapy. Methods of respiratory support preventing the need for artificial lung ventilation (ALV) are now clinically available for patients with COVID-19. This clinical review focuses on respiratory support algorithms (oxygen therapy and CPAP) and their applicability in adult COVID-19 patients. Brief recommendations for performing respiratory support in this category of patients include the following provisions: 1) medical personnel should use a maximum of personal protective equipment (respirators/masks FFP3 N-95, eye protection [face shield, goggles]), taking into account the aerosol-generating potential of devices for non-invasive respiratory support; 2) emergency oxygen therapy is required for all patients with COVID-19 who have SpO2 <92% on room air (FiO2=21°%) or they have PaO2 <55 mmHg (<7.0 kPa); 3) thermal helium-oxygen mixture (t-He/O2) and high-flow nasal oxygen therapy (HFNOT) are preferred for COVID-19 patients with a high demand for oxygen support; 4) respiratory support in the mode of continuous positive airway pressure (CPAP) with a high oxygen flow is the most justified therapy that reduces the high risks of nosocomial contamination; 5) early intubation and artificial lung ventilation are reasonable and necessary for patients with progressive respiratory failure, with the development of multiple organ failure, acute respiratory distress syndrome.
Pharmateca. 2020;27(10):19-26
pages 19-26 views

Therapeutic and diagnostic aspects of the new coronavirus infection COVID-19 in obstetric practice

Kakhiani E., Korobkov N., Vasiliev V., Romanova E.

Resumo

The purpose of this review is to summarize the global experience in the diagnosis and treatment of the new coronavirus infection COVID-19 in obstetric patients, which can be applied in the practical work of antenatal clinics and maternity hospitals in a pandemic. The current COVID-19 pneumonia pandemic is a serious public health problem, especially for vulnerable populations. Pregnant women and newborns represent a high risk group during outbreaks of infectious diseases. To date, the literature describes the perinatal outcomes of385 pregnant women infected with COVID-19, with no clinical evidence of vertical transmission. The review analyzes published data on the Wuhan coronavirus infectious potential to cause the maternal, fetal and newborn morbidity, and other adverse obstetric outcomes. The controversial issues of the etiotropic treatment of CoV-pneumonia and the existing diagnostic problems are discussed. Particular attention is paid to ensuring safety in obstetric institutions. At present, the most urgent issues include the search for antiviral drugs with the most proven efficacy and safety for the pregnant woman and the fetus, and the validation of vaccines being created.
Pharmateca. 2020;27(10):27-37
pages 27-37 views

COVID-19: selected clinical aspects through the prism of practical experience

Belotserkovskaya Y., Lebedev S., Vakatov D., Demina I., Sakara O., Romanovskikh A., Smirnov I.

Resumo

Since the first report in December 2019 of a new coronavirus infection, dubbed COVID-19, the new human coronavirus strain SARS-CoV-2 has spread worldwide, reaching pandemic proportions. Much remains to be studied, and the challenges for the near future include improvement of our understanding of the epidemiology, pathophysiology, and clinical features of this new infectious disease. There are many questions regarding the interaction of the virus and the human body. Until now, the effectiveness of any of the antiviral drugs has not been proven. This article highlights some aspects of the pathogenesis and clinical course of COVID-19, as well as the possibilities for optimizing therapy associated with these aspects. The multifaceted, sometimes excessive and uncontrollable response from the immune system determines an extremely variable spectrum of clinical manifestations of COVID-19, which ranges from asymptomatic to fatal bilateral pneumonia and multiple organ failure. «Cytokine storm» appears to be one of the most serious and potentially life-threatening events associated with the most severe clinical course of COVID-19, including the development of acute respiratory distress syndrome. Antiinflammatory therapy, including anti-interleukin-6 receptor antibodies, and timely and adequate respiratory support have no doubt proven to be effective in the treatment of these difficult patients. Chronic respiratory diseases such as bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD) can dramatically affect the fate of a patient infected with SARS-CoV2. Therefore, preventive measures to prevent nfection and the continuation of basic therapy for asthma and COPD, including inhaled glucocorticosteroids, are strongly recommended to reduce the risk of exacerbation of chronic disease, on the one hand, and improve the outcomes of COVID-19, on the other.
Pharmateca. 2020;27(10):38-51
pages 38-51 views

Treatment of a new coronavirus infection (COVID-19): opportunities and limitations

Fesenko O., Sibiryakova O., Shvayko S.

Resumo

The continuing increase in the incidence of the new coronavirus infection makes rational therapy for COVID-19 one of the urgent problems of modern medicine. Based on the analysis of modern federal guidelines, the principles of etiotropic and pathogenetic treatment of COVID-19 are considered. The article provides an analytical review of the drugs recommended in the last, eighth version of the temporary Ministry of Health of the Russian Federation guidelines «Prevention, diagnosis and treatment of a new coronavirus infection (COVID-19)», dated 03.09.20, and other sources.
Pharmateca. 2020;27(10):52-60
pages 52-60 views

Formula for successful chronic obstructive pulmonary disease control

Sinopalnikov A.

Resumo

Current guidelines for the management of patients with chronic obstructive pulmonary disease (COPD) are not sensitive enough to detect changes in the condition of COPD patient, which would indicate future risks. The article describes a new concept of «COPD control», which implies maintaining the current clinical status with the least impact of the disease symptoms in combination with a stable course, characterized by a low risk of exacerbations over a long period of time, adapted to the severity of the disease.
Pharmateca. 2020;27(10):61-71
pages 61-71 views

Clinical experience of sublingual allergen-specific immunotherapy of allergic rhinitis in a coronavirus pandemic

Orlova E., Kostina E., Kulikova O.

Resumo

Background. In recent years, there has been a significant increase in the incidence of allergic rhinitis (AR). According to official statistics, every third adult Russian suffers from AR, and official statistics do not reflect the real situation. The article presents the experience of using sublingual allergen-specific immunotherapy (SLIT) in patients with perennial and seasonal AR (PAR and SAR) caused by sensitization to pollen allergens and house dust mites in a coronavirus infection (CVI) pandemic. Objective.Evaluation of the efficacy, safety and tolerability of SLIT in AR patients in the COVID-19 pandemic. Methods. 53 patients with AR were examined, including 21 - with PAR and 32 - with SAR. From 2017 to 2020 patients received SLIT with etiotropic allergens. The control of the course of AR in patients was assessed in dynamics according to the frequency and severity of nasal symptoms, taking into account the need for medicines, the visual analogue scale (VAS) score, the need for basic therapy, allergic-immunological parameters (total IgE, asIgE to household and pollen allergens, eosinophilic cationic protein (ECP), diameter of scarification tests with allergens). Results. At the end of the full course of treatment, the clinical efficacy of SLIT with Staloral “Birch pollen allergen”, taking into account excellent and good results, was 95.5%, with Oralair - 100.0%, with Staloral “Mite allergen” - 95.3% . The frequency of exacerbations in patients with PAR decreased by 7 times, in patients with SAR - by 6.2 times. Patients have increased control over the course of AR: the total score of the AR control questionnaire decreased against the background of SLIT by the Staloral «Birch pollen allergen» from 11.0 to 3.3 points, by the drug Oralair - from 10.2 to 4.2 points, by the drug Staloral «Tick allergen» - from 9.1 to 4.0 points; the MS score decreased from 52.1 to 18.1, from 52.0 to 22.2 and from 46.2 to 15.1 points, respectively (p<0.05). Against the background of SLIT in patients with PAR, the total IgE level decreased by 1.9 times, asIgE to household allergens - by 3.4 times (from 4.88 to 1.44 kU/L), the diameter of skin tests - by 1.4 times, ECP - by 2 times (from 32.65 to 16.01 ng/ml; p<0.05). In patients with SAR, the total IgE level decreased by 2.0 times, asIgE to tree allergens - by 3.2 times (from 5.23 to 1.65 kU/L), to cereal grasses - 2.8 times (from 4.64 up to 1.66 kU/L), the diameter of skin tests - by 2.6 times, ECP - by 2.8 times (from 33.98 to 12.11 ng/ml; p<0.05)., Mild adverse events in the form of local reactions were observed in 39.6% of cases. During the CVI pandemic, follow-up of patients was carried out using telemedicine technologies. In only one patient, SLIT was temporarily suspended due to mild COVID-19. Conclusion. SLIT is a safe and high effective method of AR immunotherapy, which can be carried out despite the patient’s self-isolation regimen due to COVID-19 infection.
Pharmateca. 2020;27(10):72-79
pages 72-79 views

Possibilities of achieving of bronchial asthma control against the background of baseline therapy with beclometasone/formoterol extrafine fixed combination: an open observational prospective study

Pirogov A., Prikhodko A., Perelman N., Afanasyeva E., Kochegarova E., Oshur L., Perelman J.

Resumo

Background. The effectiveness of beclomethasone dipropionate/formoterol fumarate (BDP/FF) extrafine fixed combination is attributable to the anti-inflammatory effect on the small airways. The effect of the drug on the level of control of bronchial asthma (BA) in patients with cold and/or osmotic airway hyperresponsiveness has not been established. Objective. Evaluation of the possibility of achieving disease control against the background of therapy with BDP/FF extrafine fixed combination in patients with uncontrolled BA with cold and osmotic airway hyperresponsiveness. Methods. In 23 patients with uncontrolled BA and cold and/or osmotic airway hyperresponsiveness, asthma symptoms were assessed on a 5-point scale (Asthma Control Test - ACT); lung function (FEV1, MEF25-75) was evaluated before and after inhalation of a short-acting beta-agonist (SABA); inflammatory cells in sputum were examined initially and after 12-week use of BDP/FF extrafine fixed combination (100/6.0 pg) twice a day. Results. 7 days before treatment, 87% of patients had daily asthma attacks, 96% took additional SABA, mean ACT score was 13.8±0.79 points, FEV1 - 90.5±2.6%, MEF25-75 - 61.5±4.7%. After 6 weeks of treatment, ACT score >20 points were achieved by 74% of patients (mean 19.6±1.1 points; p=0.0008), FEV1 was 96.3±3.0%, and MEF25-75 - 68.6±4.7%. After 12 weeks, only 42% of patients had rare asthma attacks (x2=30.1; p<0.001), 52% continued to take SABA 1-2 times a week (x2=8.76; p<0.01). Good control was recorded in 90% of patients, and mean ACT score was 22.5±0.53 points (p<000001), FEV1 increased to 100.4±2.8% (p=0.013), MEF25-75 - to 76,7±4.4% (p=0.007). The reaction of the bronchi (AFEV1,%) to the administration of SABA decreased from 17.7±3.5 to 8.7±1.9% (p=0.001), the number of eosinophils in sputum - from 12.7±2.9 to 3, 2±0.9% (p=0.012). Conclusion. The treatment of patients with BDP/FF extrafine fixed combination for 12 weeks made it possible to achieve a controlled course of the disease without increasing the glucocorticoid dose, improve the respiratory function in patients with uncontrolled asthma and cold and/or osmotic airway hyperresponsiveness, and reduce sputum eosinophilia.
Pharmateca. 2020;27(10):80-87
pages 80-87 views

The role of leukotrienes in the pathogenesis of inflammation in patients with different phenotypes of bronchial asthma and chronic obstructive pulmonary disease

Kostina E., Trushina E., Orlova E., Baranova N., Levashova O.

Resumo

Background. Leukotrienes (LT) are involved in the pathogenesis of inflammation in bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD). LT is a metabolic product of arachidonic acid. There are cystenyl (C4, D4, E4) and dihydroxyl (B4) LT. LT C4, D4, E4 have a powerful bronchoconstrictor effect, LT B4 serves as a chemoattractant for neutrophils. Objective. Comparative assessment of the role of LT in patients with different phenotypes of BA and COPD. Methods. Four groups of patients were examined: 1st (n=57) - patients with allergic BA (ABA), 2nd (n=68) - patients with non-allergic BA (NABA), 3rd (n=43) - patients with aspirin-induced asthma (AIBA), group 4 (n=65) - patients with COPD. Results. A high total LT C4, D4, E4 level was observed in patients with ABA, to a lesser extent in AIBA compared to their values in patients with NABA, COPD and the control group. LT B4 values were significantly increased in patients with AIBA and COPD compared with ABA, NABA and the control group. There was a statistically significant positive correlation of total LT C4, D4, E4 with the blood eosinophil number (r=0.62, p<0.05) and with the eosinophilic type of inflammation (r=0.70, p<0.05). There was a correlation between LT B4 and neutrophils (r=0.52, p<0.05) and neutrophilic type of inflammation (r=0.56, p<0.05). Conclusion. LT plays an important role in the pathogenesis of airway inflammation in BA and COPD. In the pathogenesis of eosinophilic inflammation in ABA, total LT C4, D4, E4 prevail. LT B4 plays a significant role in neutrophilic inflammation in NABA and COPD. AIBA is characterized by a mixed type of inflammation (eosinophilic-neutrophilic), with increased level of both total LT C4, D4, E4, and LT B4. Thus, LT can be considered as markers of types of inflammation. Clarification of the types of inflammation will make it possible to personalize therapy and increase the effectiveness of treatment of patients with BA and COPD.
Pharmateca. 2020;27(10):88-93
pages 88-93 views

Bronchopulmonary dysplasia in children in terms of genetic variability of the vitamin D receptor

Sergienko D., Khishtilova P.

Resumo

Background. In addition to the main function of regulating calcium-phosphorus metabolism, vitamin D (VD) and its receptor (VDR) have an indirect effect on more than 300 genes that affect the cell cycle, immunity and metabolism. Of more than 30 known single nucleotide sequences, ApaI (rs7975232), BsmI (rs1544410), FokI (rs2228570), TaqI (rs731236), and Cdx2 (rs11568820) are the most studied and have phenotypic effects on a number of diseases. Objective. Determination of the effect of the VDR gene FOK1 polymorphism on the course and outcomes of bronchopulmonary dysplasia (BPD) in children. Methods. The main group in the study consisted of 80 patients with a diagnosis of bronchopulmonary dysplasia (BPD). The control group consisted of 93 preterm infants without BPD. All patients of the main group were examined and received treatment in accordance with the standard of medical care for this disease. To perform molecular genetic analysis, total DNA was isolated from whole blood. Genotyping of polymorphic markers of the studied genes was carried out using polymerase chain reaction (PCR) and analysis of restriction fragment length polymorphism (RFLP analysis). Statistical analysis was carried out by methods of variation statistics. Results. The association of the VDR gene FOK1 polymorphism with the implementation of BPD in children has been proven. According to statistical analysis, the F/F genotype predisposes to the development of the disease (х2=7.133; p=0.008, df=1, OR=2.811, CI: 1.3006.077). The evaluation of the effect of genotypes of the VDR gene FOK1 polymorphism on the outcomes of BPD, the severity and the implementation of broncho-obstructive syndrome in BPD exacerbation, the nature of the airway microbiota and the duration of IGCS use did not reveal statistically significant differences. At the same time, a comparative analysis of the data showed that heterozygous carriers of the F/f genotype of the VDR gene FOK1 polymorphic marker significantly more often had severe lesions of the central nervous system - CNS (x2=7.619; p<0.05, p=0.006, df=1, odds ratio [OR]=9,000, confidence interval [CI]: 1.638-49.447). Analysis of the data obtained revealed a significant relationship between the heterozygous F/f genotype of the VDR gene FOK1 polymorphic marker with the incidence of acute respiratory viral infections (ARVI) (x2=3.889; p=0.049, df=2), as well as with the appearance of the first episodes of ARVI in children up to 1-year old (x2=7.347; p<0.05, p=0.020). Conclusion. The results of the study proved that the homozygous F/F genotype is predisposing to the formation of BPD in infants. The heterozygous F/f genotype of the VDR gene FOK1 polymorphic locus is associated with vascular lesions of the central nervous system, frequent episodes and early onset of viral infections, accompanied by a severe form of obstructive syndrome in children with BPD.
Pharmateca. 2020;27(10):94-99
pages 94-99 views

Features of the course of chronic lung diseases in children at the present stage

Vyazovaya I., Ikhsanov S., Averina I.

Resumo

Background. To date, the practice of clinical observations suggests that chronic bronchopulmonary diseases in children have undergone a significant transformation over the past 10 years. This is attributable to a better understanding of etiopathogenetic mechanisms, improvement of diagnostic methods, transformation of patient therapy using new genetically engineered drugs. Objective. Comparison of the course, the nature of functional changes, and the characteristics of the microbiota of the respiratory tract in children with various forms of chronic lung disease at the present stage. Methods. 98 children were examined during the research period. All patients were divided into two main groups. The first groupwas composed of children with primary chronic lung diseases (n=42): chronic (n=30) and obliterating bronchitis (n=12). The second group included children with lung diseases that developed either against the background of malformations (n=10) or due to a genetic mutation: cystic fibrosis (n=34), immunodeficiencies (n=12). Results. According to the data obtained, exacerbations were diagnosed significantly less frequently in patients of the second group than in the first ones. According to statistical analysis, moderate exacerbations prevailed in children of both subgroups. The main characteristic of the severity of exacerbations is respiratory failure. In patients with mendelian diseases, reactive changes in the pancreas and liver were significantly more likely to occur, while in primary chronic lung diseases, damage to the central nervous system were significantly more frequent. An analysis of the nature of the microbiota and the incidence of chronic carriage of gram-negative microflora revealed the leadership of patients of the second group. Conclusion. Thus, at the present stage, despite the fact that there is a more aggressive character of the microflora of the respiratory tract and a greater decrease in functional indicators in patients with a chronic bronchopulmonary process due to genetic mutations or malformations, the frequency and severity of exacerbations are inferior to those in patients with primary chronic lung diseases.
Pharmateca. 2020;27(10):100-105
pages 100-105 views

Indications for the administration of inhaled glucocorticosteroids in patients with chronic obstructive pulmonary disease

Trushina E., Kostina E.

Resumo

Background. Respiratory tract inflammation in chronic obstructive pulmonary disease (COPD) is heterogeneous with a different response to therapy. To date, there are no exact criteria for the administration of inhaled glucocorticosteroids (IGCS). Objective. Optimization of the therapy with IGCS in COPD patients taking into account immunological inflammatory markers. Methods. 50 COPD patients, 47patients with moderate to severe allergic bronchial asthma not in exacerbation, and 17 healthy donors were examined. The number of eosinophils and neutrophils in the blood and induced sputum (IM), the blood serum eosinophilic cationic protein (ECP) and neutrophilic elastase (NE) were determined in patients. ROC analysis was carried out to determine the threshold values of the studied indicators in groups. Results. Eosinophilia in the blood was detected in 16% (n=8), in IM- in 10% (n=5) of COPD patients. An increased ESR level was detected in 12% (n=6), and an increased NE level - in 82% (n=41) of COPD patients. The ROC analysis allowed to clarify the critical values of the markers for different types of inflammation. Markers of eosinophilic airway inflammation in COPD include the number of eosinophils in IM >3.5%, ESR >19.92 ng/ml, NE <,135 ng/ml and absolute blood neutrophils <5.38x109/1. Conclusion. Markers of eosinophilic airway inflammation should be determined and taking into account for the administration of IGCS in COPD patients.
Pharmateca. 2020;27(10):106-110
pages 106-110 views

Bronchial asthma: assessment of knowledge of senior students. Final results of the ASSA-II study

Bontsevich R., Adonina A., Mikhno A., Kutsenko D., Batishcheva G., Dronova Y., Ketova G., Barysheva V., Luchinina E., Mironenko E., Bikkinina G., Pokrovskaya T.

Resumo

Background. Bronchial asthma (BA) is one of the most common non-communicable chronic diseases, affecting up to 339 million people worldwide. Asthma is a global health problem, and WHO is coordinating international efforts to control the disease. The pronounced burden of the disease is determined not only by a significant decrease in the quality of life of patients, cases of patient disability, but also by the risk of premature death. To improve the prognosis in BA, it is necessary to adhere to existing guidelines for diagnosis, treatment and prevention, as well as educate patients on how to control the existing disease. That is why it is especially important to conduct research aimed to increasing the practical knowledge of not only doctors, but also future healthcare workers. Objective. Determination of the level of basic knowledge on BA among 5th-6th year students (specialties «General Medicine» and «Pediatrics») of medical universities. Methods. Analysis of an anonymous multicenter questionnaire survey in the framework of the second phase of the ASSA project (Assessment of senior medical students in the field of bronchial asthma), conducted in 2017-2019 in 6 cities of Russia and Ukraine. Results. According to the results of the study, the level of knowledge of senior students in basic issues of etiology, pathogenesis, clinic and treatment of BA is at an above average level. The best results are shown in answers to questions № 2 (BA triggers), № 6 (BA severity) and № 9 (determination of a prolonged asthma attack), the worst - to questions № 1 (BA definition), № 3 (BA pathogenesis) and № 12 (selection of a combination of drugs in one delivery device). Conclusion. The survey showed that senior students have a sufficient knowledge base in the clinical picture and diagnosis of BA, while a number of fundamental issues related to the definition, pathogenesis and treatment of this disease still require more in-depth study.
Pharmateca. 2020;27(10):111-119
pages 111-119 views

Comparative assessment of leukotriene levels in different forms of rhinitis

Orlova E., Kostina E., Kulikova O., Levashova O., Sokolov S.

Resumo

Background. Leukotrienes (LT) as the products of the lipoxygenase mechanism of the metabolism of arachidonic acid play a significant role in the development of the inflammatory response in allergic rhinitis (АЙ) and АЙ in combination with chronic rhinosinusitis of bacterial etiology (CRSBE). Objective. Comparative assessment of the role of leukotrienes LT C4, D4, E4 and LT B4 in АЙ and АЙ with CRSBE. Methods. 83 patients with the studied forms of rhinitis aged 18 to 55 years were examined (40 patients with АЙ, 43 patients with АЙ with CRSBE). The control group included 27 apparently healthy individuals. The plasma LT levels were determined by enzyme immunoassay. In order to determine the threshold values of LT C4, D4, E4 and LT B4 levels in АЙ and АЙ with CRSBE, an ROC analysis was performed. Results. The total LT C4, D4, E4 levels are of decisive importance in the development and maintenance of the allergic mechanism of inflammation, while LTB4 predominates in the formation of a purulent-inflammatory process in these forms of rhinitis. In АЙ and АЙ with CRSBE, a high level of total LT C4, D4, E4 (3.60±0.18 ng/ml and 3.25±0.16 ng/ml, respectively) was observed in comparison with the indicators of the control group (0.64±0.12 ng/ml; p<0.05). The LTB4 level was significantly increased only in patients with АЙ with CRSBE, amounting to 14.43±0.57 ng/ml (p<0.05), while in АЙ this indicator did not differ from the values in the control group (1.89±0.19 and 1.52±0.21 ng ml, respectively). The ROC analysis of the LT level showed that the threshold value of the LT C4, D4, E4 was 1.53 ng/ ml between AR patients and healthy ones (test sensitivity 95.0%, specificity 96.3%); 1.47 ng/ml between AR patients with CRSBE and healthy ones (test sensitivity 95.3%, specificity 96.3%). For LTB4, the threshold value was 6.24 ng/ml between AR patients and AR patients with CRSBE (test sensitivity 95.3%, specificity 100.0%); 5.74 ng/ml between AR patients with CRSBE and healthy ones (test sensitivity 97.7%, specificity 100.0%). Conclusion. LT make a significant contribution to the development of an inflammatory response in the nasal mucosa in AR and AR with CRSBE. A significant role of total LT C4, D4, E4 was revealed both in AR and AR with CRSBE. These LT are responsible for the allergic component of the inflammatory response, which is consistent with the literature data. The level of LTB4, which directly supports the infectious component of inflammation in the mucous membrane of the upper respiratory tract, is elevated only in AR with CRSBE.
Pharmateca. 2020;27(10):120-124
pages 120-124 views

Efficacy and safety of mepolizumab in patients with bronchial asthma in real clinical practice

Nenasheva N., Fedosenko S., Barabanova E.

Resumo

Persistent eosinophilic inflammation in the mucous membrane of the lower respiratory tract in patients with severe bronchial asthma determines their propensity for an uncontrolled course of the disease against the background of standard pharmacotherapy, and also increases the risk of an unfavorable prognosis, including more frequent and severe exacerbations, emergency care and hospitalizations, the need for high doses inhaled and systemic glucocorticosteroids. Mepolizumab is humanized monoclonal antibody that bind free interleukin-5, as a result of which a pronounced decrease in the number of eosinophils in the blood and respiratory tract is observed. In randomized clinical trials, mepolizumab significantly reduced the frequency of asthma exacerbations and related hospitalizations, reduced the dose of oral glucocorticosteroids, significantly improved the quality of life and control of clinical symptoms, and also improved respiratory function in patients with severe eosinophilic asthma. At the same time, it is difficult to generalize data from controlled studies to the patient population in real life. This review discusses the published results of a number of open-label observational studies on the efficacy and safety of mepolizumab in patients with severe asthma in real clinical practice.
Pharmateca. 2020;27(10):125-132
pages 125-132 views

Some aspects of interstitial lung disease associated with leflunomide therapy in patients with rheumatoid arthritis

Bestaev D., Brtsieva Z., Ktsoeva S., Khutieva L., Burduli N., Kotsoeva O., Bestaeva T.

Resumo

The article analyzes publications related to interstitial lung disease (ILD) caused by taking leflunomide (LEF) during the treatment of rheumatoid arthritis. Being an effective disease modifying antirheumatic drug, LEF can provoke the development of severe forms of ILD in rheumatoid arthritis with a fatal outcome. At the same time, it is possible that the process is more acute than that of methotrexate-induced IDL. Prospective randomized controlled trials are required to further evaluation of the effect of LEF on the development and course of ILD.
Pharmateca. 2020;27(10):133-136
pages 133-136 views

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies